ATE173830T1 - Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten - Google Patents

Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten

Info

Publication number
ATE173830T1
ATE173830T1 AT94928653T AT94928653T ATE173830T1 AT E173830 T1 ATE173830 T1 AT E173830T1 AT 94928653 T AT94928653 T AT 94928653T AT 94928653 T AT94928653 T AT 94928653T AT E173830 T1 ATE173830 T1 AT E173830T1
Authority
AT
Austria
Prior art keywords
body fluid
determining
bpi
extracellular
extracellular bpi
Prior art date
Application number
AT94928653T
Other languages
English (en)
Inventor
Mark Leslie White
Stephen Fitzhugh Carroll
Jeremy Kam-Kuen Ma
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/125,677 external-priority patent/US5466580A/en
Application filed by Xoma Corp filed Critical Xoma Corp
Application granted granted Critical
Publication of ATE173830T1 publication Critical patent/ATE173830T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT94928653T 1993-09-22 1994-09-22 Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten ATE173830T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/125,677 US5466580A (en) 1993-09-22 1993-09-22 Method for quantifying BPI in body fluids
US08/175,276 US5466581A (en) 1993-09-22 1993-12-29 Method for quantifying BPI in body fluids

Publications (1)

Publication Number Publication Date
ATE173830T1 true ATE173830T1 (de) 1998-12-15

Family

ID=26823820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928653T ATE173830T1 (de) 1993-09-22 1994-09-22 Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten

Country Status (12)

Country Link
US (1) US5821064A (de)
EP (1) EP0720745B1 (de)
JP (2) JPH09503296A (de)
CN (1) CN1133634A (de)
AT (1) ATE173830T1 (de)
AU (1) AU697356B2 (de)
CA (1) CA2172243C (de)
DE (1) DE69414871T2 (de)
DK (1) DK0720745T3 (de)
ES (1) ES2126151T3 (de)
NZ (1) NZ274083A (de)
WO (1) WO1995008773A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
DE69703689T2 (de) 1996-05-10 2001-05-10 Xoma Technology Ltd., Berkeley Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
NZ332954A (en) * 1996-05-23 2000-07-28 Xoma Corp Use of BPI protein products to treat humans with hemorrhage due to trauma
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
JP6651794B2 (ja) * 2015-11-05 2020-02-19 富士レビオ株式会社 心筋トロポニンｉ測定試薬及び方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245013A (en) * 1985-04-30 1993-09-14 Richard Ulevitch Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
WO1993006228A1 (en) * 1991-09-26 1993-04-01 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
AU669723B2 (en) * 1992-05-19 1996-06-20 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
JPH08509703A (ja) * 1993-03-12 1996-10-15 ゾーマ コーポレイション 殺菌／透過性増加タンパク質産物の治療用途
CA2157925C (en) * 1993-03-12 2000-06-06 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
AU6522794A (en) * 1993-03-22 1994-10-11 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis

Also Published As

Publication number Publication date
CA2172243A1 (en) 1995-03-30
DE69414871T2 (de) 1999-06-10
DE69414871D1 (de) 1999-01-07
WO1995008773A1 (en) 1995-03-30
CN1133634A (zh) 1996-10-16
HK1014207A1 (en) 1999-09-24
ES2126151T3 (es) 1999-03-16
EP0720745B1 (de) 1998-11-25
US5821064A (en) 1998-10-13
AU697356B2 (en) 1998-10-01
JP2003315334A (ja) 2003-11-06
DK0720745T3 (da) 1999-06-23
JPH09503296A (ja) 1997-03-31
CA2172243C (en) 2002-06-18
NZ274083A (en) 1998-02-26
AU7801094A (en) 1995-04-10
EP0720745A1 (de) 1996-07-10

Similar Documents

Publication Publication Date Title
ATE182216T1 (de) Verfahren zur quantifizierung von lbp in körperflüssigkeiten
ATE133790T1 (de) Verfahren zum in vivo-nachweis von knochenresorption
ATE128183T1 (de) Peptide und antikörper, die die bindung von blutplättchen verhindern.
EP1710253A3 (de) Tumormarker
DE69109236D1 (de) Verfahren und Systeme zur Identifizierung von Flüssigkeiten und Bestimmung der Strömung.
ATE173830T1 (de) Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
ATE258310T1 (de) Testverfahren für collagenpeptid
DE3888998D1 (de) Verfahren zur Bestimmung eines Antikörpers in menschlichen Körperflüssigkeiten.
DE69105978D1 (de) Verfahren zur verminderung von störungen in einer fluoreszenzbestimmung.
NO953770L (no) Analysemetode
DE69636749D1 (de) Methode zur bestimmung von proteinfragmenten in körperflüssigkeiten
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
DE60036935D1 (de) Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls
ATE223055T1 (de) Verfahren zur diagnose von chlamydia in einer biologischen extrazellulären flüssigkeit
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
DE69618451D1 (de) Verfahren zur feststellung einer allergie
ATE184286T1 (de) Hgpiib-fragmente und ihre verwendung in in-vitro- verfahren zur bestimmung von in vivo stattfindenden thrombotischen ereignissen
ATE213835T1 (de) Verfahren zur bestimmung und zum nachweis von spenderorganschäden nach xenotransplantation auf der grundlage von aus dem spenderorgan freigesetzten analyten
DE69625236D1 (de) Verfahren zur reihenuntersuchung auf prostatakrebs durch messung des apolipoprotein-d-spiegels in körperflüssigkeiten
ATE389175T1 (de) Verfahren zur prüfung von antigenen, die mit durch mentalen stress bedingten erkrankungen assoziiert sind
ATE251309T1 (de) Verfahren zur bestimmung eines erhöhten sterblichkeitsrate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee